regeneron pharmaceuticals inc regn said wednesday it would pay 4 a share for decibel therapeutics inc dbtx  a 43 premium over its closing price of 279 a share in the previous session bostonbased decibel therapeutics is a clinicalstage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance regeneron’s acquisition price values decibel therapeutics at 109 million decibel therapeutics stock is up 36 so far in 2023 compared to a 327 increase by the nasdaq